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Fig. 1. Clinical entities in which inotropes are used.
Acute heart failure (AHF) often overlaps with advanced
vast majority of patients AHF suffer from acute decompe
the syndrome. Cardiogenic shock (CS) represents a sub
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Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third
pharmacological pillar in the treatment of patients with decompensated heart failure, the other two
being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently
indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and
dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III
inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share
some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the
patients in need of inotropic support and selecting the proper inotrope in each case remain challenging.
The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this
very issue in the setting of both acute and advanced heart failure.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction outcomes may also be related to the fact that their use is sometimesInotropes aim at increasing cardiac output by enhancing cardiac
contractility. They constitute the third pharmacological pillar in the
treatment of patients with decompensated heart failure (HF), the
other two being diuretics and vasodilators [1]. Decompensated HF
patients who need inotropic support belong to two distinct, though
partly overlapping, subpopulations, namely acutely decompensated
or acute HF (AHF) and advanced HF (AdvHF, Fig. 1). Acute HF is
characterized by a rapidly or gradually evolving hemodynamic
derangement, characterized usually by congestion and less
commonly by low cardiac output [1]. Advanced HF, on the other
hand, represents a severe, sometimes end-stage, form of the syn-
drome, characterized usually by low cardiac output, with or without
congestion [2]. In either conditions, treatment with inotropes may
be needed to manage low cardiac output that results in end-organ
hypoperfusion, with or without hypotension, despite adequate or
even elevated filling pressures. Besides symptomatic improvement,
however, there is no compelling evidence suggesting a survival
benefit of inotropes by a series of clinical studies [3,4]. In contrast,
some inotropes have even been associated with increased short and
long-term mortality in clinical trials [5,6] and propensity score-
matched analyses of registries [7,8]. The negative effect on survival
has been attributed to a series of inherited detrimental effects of
inotropes, including myocardial ischemia, hypotension, tachycardia,
and arrhythmogenesis [9]. On the other hand, adverse inotropeAHF 
CS 
heart failure (AdvHF), as the
nsation of the chronic form of
set of AHF patients.
, A pragmatic approach to th
ional Journal of Cardiology, hinappropriate. Registry data show that inotropes are often admin-
istered in patients with normal or even increased systolic blood
pressure, including 14% of patientswith systolic blood pressure (SBP)
higher than 120mmHg (OPTIMIZE registry), 13% of those with SBP
>160mmHg (ALARM-HF registry) and 4% of those with SBP
>180mmHg (European Heart Failure Survey II), as well as in 8%e10%
of patients with HF with preserved ejection fraction (ADHERE reg-
istry) [10e13]. Therefore, there is a clear need to improve both the
identification of patients who really need inotropic support, and the
selection of the proper inotrope in each case [14].
The present consensus document sought to address the issue of
inotrope use in the setting of both AHF and AdvHF. The paper
summarizes the key messages derived by an expert panel meeting,
organized by the Heart Failure Unit of the Second Department of
Cardiology, Attikon University Hospital, National and Kapodistrian
University of Athens, Greece, held in Athens in September 2018 and
attended by experts from 21 countries (Austria, Belgium, Croatia,
Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Ger-
many, Greece, Hungary, Israel, Italy, Poland, Russia, Slovenia, Spain,
Sweden, Switzerland, and Turkey).2. Current inotropes
Based on the main mechanism of action, there are three classes
of parenterally administered inotropes currently indicated for the
treatment of decompensated HF, (i) the beta adrenergic agonists,
including primarily dopamine and dobutamine and also the cate-
cholamines epinephrine and norepinephrine, (ii) the phosphodi-
esterase III inhibitor (PDEi) milrinone and enoximone and (iii) the
calcium sensitizer levosimendan (Table 1) [14].2.1. Beta agonists
b-agonists stimulate the sarcolemmal beta-1 adrenergic recep-
tor of cardiomyocytes, leading to increased activation of intracel-
lular adenyl cyclase, increased synthesis of cyclic adenosine
monophosphate (cAMP), increased release of Ca2þ from sarco-
plasmic reticulum and thus enhanced actin-myosin interaction and
ultimately increased contractility, by means that also increase
myocardial oxygen demand [15]. The different beta agonists bear
diverse pharmacologic properties because of their diverse affinitye use of inotropes for the management of acute and advanced heart
ttps://doi.org/10.1016/j.ijcard.2019.09.005
Table 1
Inotropic agents in current use for the treatment of heart failure (modified from Bistola V & Chioncel O [31]).
Adrenergic receptors agonists Calcium sensitizer PDE III inhibitor
Agents Dopamine Dobutamine Nor-epinephrine Epinephrine Levosimendan Milrinone
Mechanism of action D> b; HD, a b1> b2> a a> b1 > b2 b1¼ b2> a Calcium sensitization;
HD, PDE III inhibition
PDE III inhibition
Inotropic effect [[ [[ ([) [[ [ [
Arterial vasodilatation [[ (renal, LD) [ 0 [ [[ [[[
Vasoconstriction [[ (HD) [ (HD) [[ [ (HD) 0 0
Pulmonary
vasodilatation
[ or 0 Y or 0 (at high PVR) Y or 0 (at high PVR) [[ [[
Elimination t½ 2min 2.4min 3min 2min 1,3 h
(active metabolite, 80 h)
2,5 h
Infusion dose <3 mg/kg/min: renal
vasodilation;
3e5 mg/kg/min: inotropic;
>5 mg/kg/min
vasoconstrictor
1e20 mg/kg/
min
0.02e10 mg/kg/
min
0.05e0.5 mg/kg/min 0.05e0.2 mg/kg/min 0.375e0.75 mg/kg/
min
Bolus dose No No No 1mg during
resuscitation
every 3e5min
6e12 mg/kg over 10min
(optional, only in
euvolemic
and eukalemic state)
25e75 mg/kg over
10e20min
PDE: phospodiestarase; D: dopaminergic receptors; HD: high dose; LD: low dose; PVR: pulmonary vascular resistances; CS: cardiogenic shock.
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Dopamine is an endogenous molecule. At low doses (0.5 to
2.5 mg/kg/min), it causes renal and splanchnic vasodilation and
increase in renal blood flow, independently of cardiac output,
through the activation of dopaminergic receptors 1 and 2. At
moderate doses (3 to 5 mg/kg/min), it exerts mainly inotropic and
chronotropic effects through beta-1 receptors, while at higher
doses (>5 mg/kg/min), it causes vasoconstriction by stimulating
alpha-1 adrenergic receptors [16].
Dobutamine is a synthetic analogue of dopamine with mainly
inotropic and less chronotropic properties. At low doses (<5 mg/kg/
min), it induces inotropic and mild vasodilatory effects that may
cause hypotension, while at higher doses (>10 mg/kg/min), it exerts
inotropic, chronotropic, and mild vasoconstrictive actions.
Norepinephrine is a vasoconstrictor rather than an inotropic
agent through its action on alpha-1 receptors and, in the case of HF,
is usually used in combination with classical inotropes in cardio-
genic shock to restore blood pressure or in association with
dobutamine or inodilators to avoid hypotension. Epinephrine
causes vasodilation at low doses (<0.01 mg/kg/min) and inotropy
along with vasoconstriction at higher doses (0.05e0.5 mg/kg/min).
It is used primarily in the setting of cardiac arrest. Epinephrine may
result in lactic acidosis while its use in cardiogenic shock has been
associated with increased mortality and should be avoided [17].
2.2. The phosphodiesterase III inhibitors
Phosphodiesterase III inhibitors includemilrinone and enoximone,
although the latter is not currently available or in use in many coun-
tries. Phosphodiesterase III inhibitors increase intracellular cAMP levels
in cardiomyocytes by inhibiting its breakdown by the sarcoplasmic
reticulum-associated phosphodiesterase III, thus increasing intracel-
lular Ca2þ. Besides their inotropic effect, they also cause peripheral and
pulmonary vasodilatation and thus a drop in systemic and pulmonary
pressure and resistance through an effect on vascular smooth muscle
cells. On the other hand, due to their pharmacokinetic and pharma-
codynamic characteristics, they induce tolerance [18] as well an in-
crease in vascular resistance in end-organs [19].
2.3. The calcium sensitizer levosimendan
Levosimendan exerts its inotropic effects through sensitizationPlease cite this article as: D. Farmakis et al., A pragmatic approach to th
failure: An expert panel consensus, International Journal of Cardiology, hof cardiac troponin C to Ca2þ, without increasing the intracellular
Ca2þ concentration, thus without disturbing relaxation or myocar-
dial oxygen consumption/supply balance. Levosimendan also causes
vasodilation by activation of the ATP-sensitive Kþ channels in
vascular smooth muscle cells, while at higher doses, it also acts as a
PDEi. In addition to its hemodynamic effects, levosimendan has
further been shown to bear pleiotropic properties beyond HF and
the heart, including protection of myocardial, renal, hepatic and
neural cells from ischemia/reperfusion injury, and further anti-
inflammatory and anti-oxidative effects [20]. These properties
seem to be primarily related to the activation of ATP-sensitive Kþ
channels in mitochondria [21]. Another particular feature of the
drug is the prolonged action, compared to other inotropes, that lasts
several days after discontinuation of the infusion, which is provided
by the long elimination half-life of the active metabolite OR-1896 of
approximately 80 h. In patients with severe renal dysfunction, the
elimination half-life may be extended up to 1.5 fold, prolonging
further the action of the drug. In a review of different meta-analyses,
levosimendanwas consistently associated with lower mortality that
reached statistical significance in most of the studies [22].2.4. Comparing the properties of inotropes
It has been shown that all of the above inotropic agents, besides
increasing cardiac contractility, also bear vasoactive properties,
causing either vasoconstriction, as in the case of norepinephrine,
epinephrine and high-dose dopamine or vasodilation, as in the case
of PDEi, levosimendan and low-dose dobutamine. These properties
should be taken under consideration when choosing among the
different inotropes. Due to their combined inotropic and vasodilating
effects, PDEi and levosimendan are often referred to as inodilators.
Inotropes bear a non-negligible risk of important adverse
events. Dopamine may induce tachyarrhythmias, particularly at
high doses [16]. Dobutamine, apart from tachyarrhythmias, also
causes hypotension at low doses due to vasodilation. Norepineph-
rine may indirectly induce arrhythmias by unbalancing myocardial
oxygen supply-demand and increasing systemic vascular resis-
tance. Epinephrine has several adverse effects including tachyar-
rhythmias, myocardial ischemia and systemic or pulmonary
hypertension. Milrinone causes tachyarrhythmias and profound
arterial hypotension, while it should be used with caution in pa-
tients with impaired or deteriorating renal function. Levosimendane use of inotropes for the management of acute and advanced heart
ttps://doi.org/10.1016/j.ijcard.2019.09.005
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encountered form of arrhythmia is atrial fibrillation, while the
arrhythmogenic effect of the drug is less pronounced compared to
other inotropes due to the avoidance of cardiomyocyte calcium
overload [20,23]. Furthermore, limited data shows that the hypo-
tensive effect of levosimendan may not require an excessive in-
crease in vasopressors in cardiogenic shock [24] as in the case of
PDEi [25]. Both adverse events may be avoided or restricted if no
loading dose is administered [20].
3. Inotropes in acute heart failure
Acute HF is defined as the new onset of or change in symptoms
and signs of HF that requiresmedical intervention and usually leads
to hospitalization [14]. Acute HF encompasses a wide spectrum of
clinical conditions, ranging from mild and gradually developing
central and peripheral congestion in the presence of chronic HF, to
abrupt congestionwith acute pulmonary edema caused by an acute
hemodynamic derangement, such as a hypertensive peak, to low
output syndromes and to cardiogenic shock [26]. Prognosis varies
accordingly, with in-hospital mortality ranging between 2% and
40% at the two ends of the spectrum, respectively [27,28].
No pharmacologic therapies, including either classical drugs or
novel and investigational agents, have hitherto been shown to
improve outcomes in AHF in terms of hard endpoints (Supple-
mentary Table 1). As a result, recommendations for the manage-
ment of AHF include etiological treatment, when a specific treatable
cause or precipitant is identified, such as acute coronary syndromes,
along with the alleviation of symptoms caused by congestion and
the restoration of cardiac output in the case of low output states.
In AHF, inotropes are required for the treatment of the subset of
patients with low cardiac output, resulting in persistent symp-
tomatic hypotension and/or end-organ hypoperfusion, despite
adequate intravascular volume. In the ESC-Heart Failure Long-Term
Registry, inotropes were used in 12% of patients admitted with AHF
[8]. Epidemiological evidence shows that patients with low cardiac
output and peripheral hypoperfusion comprise <10% of the AHF
population, but this particular subpopulation bears the worst
prognosis with the highest mortality rates [29]. In these patients,
current guidelines recommend the use of any of the aforemen-
tioned inotropic agents with a class IIb recommendation [14]. It
should be stressed that the use of inotropes should be limited to the
lowest dose and the shortest possible period of time.
Identifying the patients with true end-organ hypoperfusion can
be challenging. Symptoms, signs and laboratory findings that can
be used as criteria to decide the presence of peripheral hypo-
perfusion include persistent hypotension, cold and wet extremities,
mottled skin, altered mental status, oliguria, low cardiac index,
elevated serum lactate, elevated serum transaminases or low
venous oxygen saturation [14]. These criteria should be used in
combination and it is important to remember that peripheral
hypoperfusion may occur even in the absence of significant hypo-
tension, due to sympathetic activation causing a profound periph-
eral vasoconstriction [30]. At the same time, hypovolaemia should
always be excluded based on signs and tests of adequate intravas-
cular volume, such as presence of normal or elevated central
venous pressure, lack of inferior vena cava distensibility, negative
fluid challenge or negative passive leg raising test.
Treatable causes of AHF, such as acute coronary syndrome,
pulmonary embolism, mechanical complications of myocardial
infarction, tachyarrhythmias or valvular disorders should be timely
diagnosed and managed accordingly [14]. In the latter case, ino-
tropesmay still be needed in combinationwith or as a bridge to the
treatment of the relevant etiology. Furthermore, viable alternatives
to inotropes, such as mechanical circulatory support withPlease cite this article as: D. Farmakis et al., A pragmatic approach to th
failure: An expert panel consensus, International Journal of Cardiology, htemporary ventricular assist devices or extracorporeal membrane
oxygenation (ECMO), should also be explored, particularly in pa-
tients not adequately responding to inotropes.
Once inotropes are deemed necessary, the choice of the proper
agent should be based on patient’s profile as determined by medical
history, background medications, hemodynamic status and comor-
bid conditions [31]. In patients with decompensated ischemic HF
without true hypoperfusion, milrinone showed a deleterious effect
[32], while levosimendan has been associated with a trend towards
survival improvement in different meta-analyses [22]. Thus, it has
been proposed that levosimendan or dobutamine are more prefer-
able options, despite the absence of direct head-to-head compari-
sons [33]. In patients with right ventricular failure and/or pulmonary
hypertension, milrinone and levosimendan are preferred due to their
vasodilatory effects on pulmonary vasculature. In terms of back-
ground medication, patients on beta blockers theoretically respond
better to levosimendan or milrinone, as these drugs act indepen-
dently of the b-adrenergic receptors; the same is true in the case of
beta-1 receptor down-regulation that has been noticed in HF [34].
Concerning the hemodynamic status, in the presence of persistent
hypotension, besides adequate volume status, norepinephrine is the
vasopressor of choice and can be used in combination with vaso-
dilating inotropes such as dobutamine and levosimendan in an effort
to enhance cardiac contractility while maintaining adequate blood
pressure for tissue perfusion; vasopressor may subsequently be
withdrawn with the amelioration of cardiac performance [35]. The
combination of two different classes of inotropes, in contrast, does
not seem to provide additional benefit. With respect to comorbid-
ities, in patients with primary renal failure, one should consider the
long half-lives of milrinone and levosimendan (Table 1). In patients
with cardiorenal syndrome in the context of AHF, levosimendanmay
be the proper option. In a small study in AHF, levosimendan
improved glomerularfiltration rate alongwith increasing renal blood
flow and renal artery diameter [36], while the drug has further been
shown to bear reno-protective effects in experimental and clinical
studies [21,37]. Finally, in AHF-associated cardio-hepatic dysfunction,
levosimendan seems to be superior to dobutamine [38].
3.1. Inotropes in cardiogenic shock
Cardiogenic shock (CS) is a particular form of AHF with ominous
prognosis and increasedmortality [39]. It is defined as the presence
of SBP <90mmHg for >30min (or need of catecholamines to
maintain SBP >90mmHg), associated with clinical signs of pul-
monary congestion as well as impaired organ perfusion with at
least one of the following: (i) altered mental status, (ii) cold and
clammy skin and extremities, (iii) serum lactate >2.0mmol/L, (iv)
oliguria with urine output <30mL/h (<0.5ml/kg/min), caused by a
cardiac condition [40]. It is associatedwith significant derangement
of tissue perfusion, resulting in a vicious circle of progressive
interrelated multi-organ dysfunction that is lethal unless proper
and timely interventions are applied.
The management of CS consists of treating the etiology - as in the
case of acute coronary syndromes that represents amajor cause of CS
- along with the hemodynamic support with inotropes and vaso-
pressors to increase cardiac output and blood pressure in order to
restore tissue perfusion. Mechanical circulatory support, with tem-
porary ventricular assist devices or ECMO, may be needed when the
patient is not responding to initial therapyor as a bridge to etiological
treatment, durable mechanical circulatory support or heart trans-
plantation. In CS, norepinephrine provides a survival advantage over
dopamine, according to a sub-analysis of the SOAP-II trial [16], and
over epinephrine, according to the OPTIMA-CC trial, in which
epinephrine induced excessive refractory HF [17]. The association of
epinephrine with increased short and medium-term mortalitye use of inotropes for the management of acute and advanced heart
ttps://doi.org/10.1016/j.ijcard.2019.09.005
Fig. 2. The variable course of decompensation in advanced heart failure.
It could be possible in many instances to identify intervals (T) during which the timely
recognition of the signs and symptoms of decompensation permit interventions that
can avert unplanned hospitalizations due to hemodynamic deterioration (modified
from Oliva et al. [65]).
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greater neurohormonal activation and myocardial and renal injury
[41]. As an example for the differential effects of inotropes, it has
been shown that patients in cardiogenic shock after cardiac surgery
requiring temporary extracorporeal life support and inotrope sup-
port for weaning may benefit from levosimendan, without an in-
crease in norepinephrine requirements, when compared to
milrinone [42]. Furthermore, a Cochrane systematic review, showed
that levosimendanmay be superior to dobutamine in terms of short-
term survival; however, this finding did not translate into a signifi-
cant long-term survival benefit, while some studies included in the
analysis were considered as low-quality evidence [43].
A propensity score-matched analysis by the GREAT network
showed that combining vasopressors (epinephrine, norepineph-
rine, or dopamine) with vasodilating inotropes (dobutamine, lev-
osimendan or PDE inhibitors) leads to better survival than
vasopressors alone [35].
4. Inotropes in advanced heart failure
Patients with AdvHF represent 1e10% of all HF patients, a
prevalence that is expected to increase because of the growing HF
population and its improving survival [2]. In 2018, the Heart Failure
Association of the European Society of Cardiology updated its
definition of AdvHF [2]; this new definition is provided in Supple-
mentary Table 2.
Patients with AdvHF suffer from severe and persistent symp-
toms, often unresponsive to drug therapy, poor performance status
with marked limitation in exercise capacity, significantly impaired
quality of life (QoL), progressive deterioration of multiple organ
function such as renal and hepatic functions, intolerance to disease-
modifying therapies and repeated hospitalizations [30]. A proposed
classification of AdvHF that identifies the involvement of other
organs besides the heart allows to distinguish AdvHF from end-
stage cardiac patients [44].
Due to the fact that AdvHF is a persistent condition, that usually
worsens over time, and may demand permanent solutions
including durable mechanical circulatory support and cardiac
transplantation, inotropes may be required repeatedly. Neutral
results on overall long-term survival are shown when pooling the
data of all studies on intermittent inotrope administration in
AdvHF, irrespectively of the drug [45,46]. In this setting, levosi-
mendanmay have an advantage over the other inotropes due to the
long-lasting effect of its active metabolite OR-1896 [47]. Indeed, a
number of clinical trials have provided encouraging evidence on
the use of repetitive levosimendan infusions in AdvHF, showing
improvement in functional status, QoL, hemodynamic outcomes,
and neurohormonal and inflammatory markers [48e51]. A meta-
analysis of 7 randomized trials including 438 patients followed
for 8months in average showed that levosimendan led to a sig-
nificant reduction in mortality and 3-month hospitalizations by
46% and 60%, respectively, compared to dobutamine or placebo
[52]. However, the multicenter randomized trial LevoRep (n¼ 120)
showed no effect on the primary endpoint of improvement in
functional capacity (6-min walked distance, 6MWD, increase by
20% or more) and QoL (Kansas City Cardiomyopathy Questionnaire,
KCCQ, improvement by 15% or more), despite a reduction in the
composite of death, heart transplantation, and acute heart failure
rates [53]. In contrast, the LION-HEART study (n¼ 69) met its pri-
mary endpoint of NT-proBNP reduction, and it further showed a
significant decline in the rate of all-cause death or HF hospitaliza-
tion [54]. A meta-analysis of all available clinical trials, confirmed
the effect of levosimendan on re-hospitalization in AdvHF [55]. The
ongoing LeoDOR trial tests the hypothesis that repetitive levodi-
mendan infusions will improve outcomes in AdvHF patients whenPlease cite this article as: D. Farmakis et al., A pragmatic approach to th
failure: An expert panel consensus, International Journal of Cardiology, happlied during the vulnerable post-discharge period, when a sig-
nificant proportion of readmissions occur [56].
Patients with AdvHF are inherently unstable and begin to
decompensate well before being hospitalized [2,57]. As illustrated
in Fig. 2, there is often a crucial interval during which the timely
recognition of signs and symptoms of decompensation can avoid
unplanned hospitalization due to haemodynamic derangement,
which seems to be followed by loss of myocardial tissue. Preventing
re-hospitalization in this window of opportunity represents
therefore and important target in this population. The effect of this
preemptive strategy based on repeated inodilators, such as levo-
simendan, remains to be proven [56,58].
5. Inotropes and patient reported outcomes
Randomized trials have generally failed to provide compelling
evidence that inotropes improve survival endpoints in patients
with HF. Still, inotropes are indispensable in the setting of both AHF
and AdvHF as they do improve patients’ symptoms. In addition,
treatment of AdvHF patients is often primarily palliative, and HF
patients seem to attachmoreweight to QoL rather than to longevity
[59]. Therefore, evaluation of the effects of inotropes on patient
reported outcomes (PRO) is important. Incorporating the patient
perspective through the evaluation of PRO is becoming increasingly
essential in clinical trials. However, large randomized trials have
not sufficiently addressed the effects of inotropes on PRO.
A key PRO that has been broadly studied in HF is QoL through
the use of a series of well-structured and usually self-administered
questionnaires and tools [60]. A number of factors affect QoL in
patients with AHF or AdvHF, besides symptoms of central and pe-
ripheral congestion, including neurohormonal and inflammatory
activation, impaired peripheral muscle perfusion and function,
comorbid conditions such as anemia or pulmonary disease, wasting
and cachexia, deconditioning, psychological impairment and
depression as well as social status [61,62]. In turn, QoL seems to be
an independent predictor of prognosis in chronic HF and impaired
QoL has been associated with reduced survival and increased event
rate [63]. In the placebo arm of the SHIFT-HF trial, impaired QoL, as
determined by the lower KCCQ tertile, was significantly associated
with increased incidence of the primary composite endpoint of
cardiovascular death and heart failure hospitalization [63]. How-
ever, the prognostic value of QoL questionnaires in AHF is limited.
Studies in refractory AdvHF patients have shown that treatmente use of inotropes for the management of acute and advanced heart
ttps://doi.org/10.1016/j.ijcard.2019.09.005
Decompensated heart failure
Step 1: 
Is there a real need for an 
inotrope? 
Step 2: 
What inotrope is the most 
appropriate?
Step 3: 
When is the proper me to 
wean the inotrope?
Adequate intravascular volume
• Normal or increased CVP
• No IVC distensibility or SVC collapsibility under 
IMV
• Negave fluid challenge (rise in filling pressure 
w/o increase in CI)
• Negave passive leg raising test
• Negave end-expiratory occlusion test or dal 
volume challenge
• SVV/PPV < 12% (when applicable)
Lack of viable alternaves
• PCI or CABG (ischemic disease with angina or 
arrhythmias)
• Mechanical circulatory support
Alternaves can be used in combinaon with or 
in the lack of response to inotropes 
• Chronic beta-blocker therapy: Levosimendan or milrinone
• Cardiogenic shock: Norepinephrine plus dobutamine or levosimendan
• RV failure and/or pulmonary hypertension: Levosimendan or milrinone
• Worsening renal funcon in cardiorenal syndrome: Levosimendan
• Ischemic heart disease: Levosimendan or dobutamine
• Sepc cardiomyopathy: Norepinephrine plus dobutamine or levosimendan
• Severe takotsubo: Levosimendan
• Repeve use for advanced heart failure: Levosimendan
Stabilizaon criteria
• Improvement of symptoms 
• Improvement of vital signs (SBP, HR, RR), SpO2, SvO2
• Improvement of invasive parameters (CI, PCWP)
• Reducon in serum lactate
• Restoraon of diuresis 
• Improvement of echo-Doppler indices
Low cardiac output
• SBP <90 mmHg for >30 min
• CI <2.2 L/min/m2
• Cold & sweated extremies
• Skin moling 
• Oliguria <30 ml/h (<0.5 ml/kg/min)
• Altered mental status
• Serum lactate >2 mmol/L
• SvO2 <60%
• Liver enzyme elevaon
Lack of treatable causes
• Acute myocardial infarcon (PCI)
• Pulmonary embolism (thrombolysis or 
thrombectomy)
• Tachyarrhythmias (cardioversion)
• Bradycardia (pacing)
• Tamponade (pericardiocenthesis)
• Valvular disease (valvuloplasty or valve surgery)
Inotropes can be used in combinaon with or as 
a bridge to causal therapies 
Fig. 3. Practical recommendations for the use of inotropes in acute heart failure.
SBP, systolic blood pressure; CVP, central venous pressure; ICV, inferior vena cava; PCI, percutaneous coronary intervention; ACS, acute coronary syndrome; HR, heart rate; RR,
respiratory rate; PCWP, pulmonary capillary wedge pressure; CABG, coronary artery bypass surgery; IMV, intermittent mechanical ventilation; SVV, stroke volume variation; PPV,
pulse pressure variation; CI, cardiac index.
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outpatient clinic or at home, improves QoL, without having an ef-
fect on survival [45]. Similarly, small studies have shown that
repeated levosimendan administration also improves functional
capacity and QoL in AdvHF [64,65]. However, as previously stated,
the two randomized trials on repeated levosimendan infusions,
LevoRep and LION-HEART, provided conflicting evidence.
6. Conclusions
Inotropes increase cardiac output by enhancing cardiac
contractility through different mechanisms of action, but they also
bear variable vasodilatory or vasoconstrictive effects depending on
agent and dosage. They constitute an important tool for the treat-
ment of patients with AHF or AdvHF, as they are often effective in
improving hemodynamics and symptoms. However, their admin-
istration has been associated with increased short and long-term
mortality due to frequent adverse effects, but also due to their
improper use. The classes of inotropes currently used in HF are the
b-adrenergic receptor agonists including dopamine, dobutamine
and the catecholamines norepinephrine and epinephrine, the PDE
III inhibitor milrinone and the calcium sensitizer levosimendan.
In AHF, inotropes are indicated with a IIb recommendation by
the ESC guidelines only for patients with peripheral hypoperfusionPlease cite this article as: D. Farmakis et al., A pragmatic approach to th
failure: An expert panel consensus, International Journal of Cardiology, hbecause of low cardiac output. Identifying patients with truly low
cardiac output in need of inotropic support can be challenging,
while selecting the proper agent according to patients’ clinical
profile and limiting infusion to the shortest time and lowest dose
possible are important to optimize inotrope use. Levosimendan
bears some pharmacological and pharmacokinetical advantages in
this setting, but its positive clinical evidence is based mainly on
observational studies, small randomized regulatory trials and
meta-analyses as the large randomized trials have hitherto pro-
vided neutral results.
In AdvHF, inotropic agents are required for the relief of persis-
tent symptoms and the improvement of quality of life. Day clinic-
based or home-based repetitive infusions may reduce hospital
admission, which is a key factor in the quality of live and perhaps
overall prognosis of the disease. Levosimendan bears an advantage
in this setting due to its long-acting active metabolite, but evidence
from properly powered randomized trials are awaited.
Fig. 3 provides a practical approach to the three main steps
required for the optimal use of inotropes in HF, namely (i) the
identification of the right patient, (ii) the choice of the proper
inotrope and (iii) the definition of the adequate weaning time.
The effects of inotropes on PRO and QoL in general, remain
poorly defined, and more studies on this important and clinically
meaningful aspect of AHF and AdvHF patient care are warranted.e use of inotropes for the management of acute and advanced heart
ttps://doi.org/10.1016/j.ijcard.2019.09.005
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